FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Raises Opinion On Shares Of Borgwarner Inc. To Strong Buy From Hold

By

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We maintain our 12-month price target of $75, based on a 2027 P/E of 13.0x, a justified premium to BWA's 10-year average forward P/E of 10.7x due to growth opportunities from new products and end markets. Following BWA's much stronger-than-expected Q1 earnings, we are raising our estimates and our rating on the shares to Strong Buy from Hold. We raise our adjusted EPS estimates to $5.25 from $5.15 for 2026 and to $5.75 from $5.60 for 2027. BWA continues to successfully navigate a difficult automotive cycle. While the company merely maintained prior 2026 guidance, we believe BWA is likely to raise guidance in subsequent quarters and see significant earnings upside in the longer term from the diversification of its product portfolio, e.g., its entrance into the AI-driven data center market, where it inked a turbine generator system project earlier this year with TurboCell (production expected to begin in early 2027 and estimated sales of more than $300M during the first year).

Related Articles

Australia

Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says

Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%

$APTV$F
Research

Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target

Price: $15.79, Change: $-4.34, Percent Change: -21.55%

$CRTO
Australia

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%

$OCUL